Sertraline plus deanxit to treat patients with depression and anxiety in chronic somatic diseases: a randomized controlled trialReportar como inadecuado

Sertraline plus deanxit to treat patients with depression and anxiety in chronic somatic diseases: a randomized controlled trial - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Psychiatry

, 15:84

Mood disorders


BackgroundPatients in chronic somatic diseases are often accompanied with depression and anxiety, remission of which may be observed in the third or fourth week after applying common antidepressant medications. We investigate the efficacy and safety of sertraline plus deanxit on patients with depression and anxiety in chronic somatic diseases.

Methods75 Patients who met the criteria were randomly assigned to deanxit group or placebo group: sertraline 75 mg-day plus deanxit one piece-day N = 38, or sertraline 75 mg-day plus placebo one piece-day N = 37 for 2 weeks, both groups received sertraline 75 mg-day in the following 2 weeks. Changes from baseline to day 4, day 8, day 15, and day 29 in Hamilton Rating Scale for Depression HAM-D and Hamilton Rating Scale for Anxiety HAM-A total scores were the efficacy measures. Adverse events were monitored and registered systematically during the trial.

ResultsResponse rates for HAM-D scores in deanxit group and placebo group were significantly different on day 855.26% ± 2.56% VS 24.32% ± 2.19%, p = 0.006 and day 1578.95% ± 3.89% VS 40.54% ± 4.18%, p = 0.001, while no statistical differences were observed on day 4 and day 29. Respectively, response rates for HAM-A scores on day 4 34.21% ± 2.21% VS 8.11% ± 1.37%, p = 0.006, day 8 57.89% ± 3.56% VS 18.92% ± 2.68%, p = 0.001 and day 15 78.95% ± 4.37% VS 43.24% ± 4.68%, p = 0.002, favoring the deanxit group. However, HAM-A scores were not remarkably different at the end point. The overall safety profile of both groups was favorable with no distinct differences.

ConclusionsThe efficacy was exhibited in the deanxit group, with evidence for similar safety. The rapid onset of sertraline plus short-term deanxit indicated that it might be an inspiring strategy to manage depression and anxiety within the first two weeks in chronic somatic diseases.

KeywordsSertraline Deanxit Depression and anxiety Chronic somatic diseases Limin Wang and Zhuoyuan Zhong contributed equally to this work.

Electronic supplementary materialThe online version of this article doi:10.1186-s12888-015-0449-2 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Limin Wang - Zhuoyuan Zhong - Jingyang Hu - Xiaoming Rong - Jun Liu - Songhua Xiao - Zhonglin Liu


Documentos relacionados